Stockreport

Marker Therapeutics Announces Upcoming Presentations on MT-601 in Relapsed Non-Hodgkin and Hodgkin Lymphoma at the 67th ASH Annual Meeting

Marker Therapeutics, Inc.  (MRKR) 
Last marker therapeutics, inc. earnings: 11/12 04:01 pm Check Earnings Report
PDF Ongoing Phase 1 APOLLO study investigating MT-601 in patients with relapsed B cell lymphomas showed encouraging preliminary efficacy data MT-601 demonstrated robust saf [Read more]